Aralez Pharmaceuticals Inc. (ARLZ) Shares Down 3.5%
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) was down 3.5% during trading on Wednesday . The stock traded as low as $4.88 and last traded at $4.93, with a volume of 514,071 shares traded. The stock had previously closed at $5.11.
Several equities research analysts have commented on ARLZ shares. Guggenheim restated a “buy” rating and issued a $12.00 price objective on shares of Aralez Pharmaceuticals in a research report on Monday. Chardan Capital restated a “buy” rating and issued a $10.00 price objective on shares of Aralez Pharmaceuticals in a research report on Sunday, August 14th.
The firm has a 50-day moving average of $3.87 and a 200 day moving average of $4.26. The firm’s market capitalization is $342.52 million.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.08. The firm earned $12.60 million during the quarter, compared to analyst estimates of $9.70 million. The company’s revenue for the quarter was up 142.3% on a year-over-year basis. On average, analysts anticipate that Aralez Pharmaceuticals Inc. will post ($0.98) earnings per share for the current year.
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.